Display options
Cite
Kierkels GJ, Straetemans T, de Witte MA, et al. The next step toward GMP-grade production of engineered immune cells. Oncoimmunology. 2015;5(2):e1076608doi: 10.1080/2162402X.2015.1076608.
Kierkels, G. J., Straetemans, T., de Witte, M. A., & Kuball, J. (2016). The next step toward GMP-grade production of engineered immune cells. Oncoimmunology, 5(2), e1076608. https://doi.org/10.1080/2162402X.2015.1076608
Kierkels, Guido J J, et al. "The next step toward GMP-grade production of engineered immune cells." Oncoimmunology vol. 5,2 (2016): e1076608. doi: https://doi.org/10.1080/2162402X.2015.1076608
Kierkels GJ, Straetemans T, de Witte MA, Kuball J. The next step toward GMP-grade production of engineered immune cells. Oncoimmunology. 2015 Aug 27;5(2):e1076608. doi: 10.1080/2162402X.2015.1076608. eCollection 2016 Feb. PMID: 27057450; PMCID: PMC4801490.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Aug 27;5(2):e1076608. doi: 10.1080/2162402X.2015.1076608. eCollection 2016 Feb.

The next step toward GMP-grade production of engineered immune cells.

Oncoimmunology

Guido J J Kierkels, Trudy Straetemans, Moniek A de Witte, Jürgen Kuball

Affiliations

  1. Laboratory of Translational Immunology, University Medical Center Utrecht , Utrecht, The Netherlands.
  2. Department of Hematology, University Medical Center Utrecht , Utrecht, The Netherlands.
  3. Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 27057450 PMCID: PMC4801490 DOI: 10.1080/2162402X.2015.1076608

Abstract

Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.

Keywords: Adoptive immunotherapy; GMP-grade production; T cell subsets; allogeneic stem cell transplantation

References

  1. Immunol Rev. 2014 Jan;257(1):127-44 - PubMed
  2. J Clin Invest. 2008 Jan;118(1):294-305 - PubMed
  3. Blood. 2012 Dec 20;120(26):5153-62 - PubMed
  4. Biol Blood Marrow Transplant. 2015 Oct;21(10 ):1839-45 - PubMed
  5. Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S6-10 - PubMed
  6. Leukemia. 2014 Jun;28(6):1181-90 - PubMed
  7. J Clin Invest. 2015 Jul 1;125(7):2677-89 - PubMed
  8. Clin Cancer Res. 2015 Sep 1;21(17):3957-68 - PubMed
  9. Blood. 2004 Feb 15;103(4):1534-41 - PubMed
  10. Cancer Immunol Immunother. 2015 Jul;64(7):893-902 - PubMed

Publication Types